Inventor
XURI GAO
Inventor
US
Overview
Patents· 15 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds37%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
A61KPreparations for medical, dental or toiletry purposes20%
C07BGeneral methods of organic chemistry10%
C07CAcyclic or carbocyclic compounds10%
PatentTitleYear
12,540,141Spiropyrrolidine derived antiviral agents202612,496,282Hepatitis B antiviral agents202512,398,147Macrocyclic spiropyrrolidine derived antiviral agents202512,145,942Spiropyrrolidine derived antiviral agents202412,054,493Hepatitis B antiviral agents202412,011,425Hepatitis B antiviral agents202411,976,084Spiropyrrolidine derived antiviral agents202411,912,714Spiropyrrolidine derived antiviral agents202411,760,755Hepatitis B antiviral agents202311,596,611Hepatitis B antiviral agents202311,472,808Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents202211,384,090Spiropyrrolidine derived antiviral agents202211,352,363Spiropyrrolidine derived antiviral agents202211,339,170Spiropyrrolidine derived antiviral agents202211,236,111Hepatitis B antiviral agents2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to ENANTA PHARM INC (15)· patent assignee history
2022–2026Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ENANTA PHARM INC | 15 | 2022–2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 15 | 2022–2026 |